Evidence map›Paper›PMID 42273003›Full record

ArticleTouchREVIEWS in endocrinology2026

Rethinking Metabolic Dysfunction in Chronic Liver Diseases.

Lung-Yi Loey Mak

Abstract readEditorial
In one paragraph

Article in TouchREVIEWS in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lung-Yi Loey MakDepartment of Medicine, School of Clinical Medicine, The Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction is a concept derived from metabolic syndrome, which is characterized by the presence of metabolic abnormalities, including obesity, diabetes mellitus, hypertension and dyslipidaemia. Metabolic dysfunction not only drives the development of metabolic dysfunction-associated steatotic liver disease but is also responsible for the heightened cardiovascular risk within the broader scope of liver-cardiovascular-kidney-metabolic syndrome. In other chronic liver diseases, metabolic dysfunction alters the natural history and might impact treatment outcomes.

Indexed as

Cardiovascular diseasecardiovascular–kidney–metabolic (CKM) syndromecirrhosishepatocellular carcinomametabolic syndromemortality

Identifiers

PMID42273003
PMCPMC13249123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.